[go: up one dir, main page]

MX2008013017A - Tratamiento de malignidades hematologicas con fts y un inhibidor de tirosina cinasa de bcr-abl. - Google Patents

Tratamiento de malignidades hematologicas con fts y un inhibidor de tirosina cinasa de bcr-abl.

Info

Publication number
MX2008013017A
MX2008013017A MX2008013017A MX2008013017A MX2008013017A MX 2008013017 A MX2008013017 A MX 2008013017A MX 2008013017 A MX2008013017 A MX 2008013017A MX 2008013017 A MX2008013017 A MX 2008013017A MX 2008013017 A MX2008013017 A MX 2008013017A
Authority
MX
Mexico
Prior art keywords
fts
bcr
abl
kinase inhibitor
hematological
Prior art date
Application number
MX2008013017A
Other languages
English (en)
Inventor
Yoel Kloog
Itay Nakdimon
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot filed Critical Univ Ramot
Publication of MX2008013017A publication Critical patent/MX2008013017A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Están descritos métodos para tratar una malignidad hematológica mediante administrar a un humano que necesita de las mismas cantidades efectivas de FTS (Ácido Farnesiltiosalicilico), o varios análogos del mismo, o una sal farmacéuticamente aceptable del mismo, opcionalmente en combinación con un inhibidor de tirosina cinasa de Bcr-Abl. También están descritas composiciones farmacéuticas que comprende FTS, o varios análogos del mismo, o una sal farmacéuticamente aceptable del mismo, un inhibidor de tirosina cinasa de Bcr-Abl, preferiblemente Imatinib y un portador farmacéuticamente aceptable.
MX2008013017A 2006-04-11 2007-04-10 Tratamiento de malignidades hematologicas con fts y un inhibidor de tirosina cinasa de bcr-abl. MX2008013017A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79105006P 2006-04-11 2006-04-11
PCT/IL2007/000439 WO2007116396A1 (en) 2006-04-11 2007-04-10 Treatment of hematological malignancies with fts and a bcr-abl tyrosine kinase inhibitor

Publications (1)

Publication Number Publication Date
MX2008013017A true MX2008013017A (es) 2008-11-27

Family

ID=38218987

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008013017A MX2008013017A (es) 2006-04-11 2007-04-10 Tratamiento de malignidades hematologicas con fts y un inhibidor de tirosina cinasa de bcr-abl.

Country Status (5)

Country Link
US (1) US20090298843A1 (es)
EP (1) EP2004170A1 (es)
CA (1) CA2648518C (es)
MX (1) MX2008013017A (es)
WO (1) WO2007116396A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006017728D1 (de) 2005-11-28 2010-12-02 Univ Ramot Krebsbehandlung mittels fts und 2-deoxyglucose
WO2011051938A1 (en) * 2009-10-26 2011-05-05 Ramot At Tel-Aviv University Ltd. Composition for treatment of thyroid cancer with fts and analogs thereof
WO2011056542A1 (en) * 2009-10-26 2011-05-12 Ramot At Tel-Aviv University Ltd. Cancer therapy with combinations of fts with hdac inhibitors
US9738614B2 (en) 2011-10-07 2017-08-22 Pisces Therapeutics, Llc Malignant and non-malignant disease treatment with Ras antagonists
US9309203B2 (en) 2011-10-07 2016-04-12 Pisces Therapeutics, Llc Malignant and non-malignant disease treatment with Ras antagonists
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
WO2017079267A1 (en) 2015-11-02 2017-05-11 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same
KR20210006356A (ko) 2018-04-04 2021-01-18 아비나스 오퍼레이션스, 인코포레이티드 단백질분해 조절제 및 연관된 사용 방법
AU2024212035A1 (en) 2023-01-26 2025-08-14 Arvinas Operations, Inc. Cereblon-based kras degrading protacs ans uses related thereto

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202456A (en) * 1991-04-15 1993-04-13 The President And Fellows Of Harvard College Compounds for inhibition of protein methylation
IL107587A (en) * 1993-11-12 1998-08-16 Univ Ramot Farnesyl geranyl or geranyl-geranyl derivatives pharmaceutical compositions containing them and methods for their preparation
US6462086B1 (en) * 1999-06-18 2002-10-08 Ramot University Authority For Applied Research And Industrial Development Ltd. Non-malignant disease treatment with Ras antagonists
AU2003248813A1 (en) * 2002-07-05 2004-01-23 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms

Also Published As

Publication number Publication date
US20090298843A1 (en) 2009-12-03
WO2007116396A1 (en) 2007-10-18
EP2004170A1 (en) 2008-12-24
CA2648518C (en) 2012-06-26
CA2648518A1 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
MX2008013017A (es) Tratamiento de malignidades hematologicas con fts y un inhibidor de tirosina cinasa de bcr-abl.
EA200800726A1 (ru) Введение ингибиторов дипептидилпептидазы
MX391624B (es) Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina.
BR112014004504A2 (pt) "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase"
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
UY32062A (es) Inhibidores de beta-secretasa
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
EA202091999A3 (ru) Применение ингибиторов dpp iv
NI200900106A (es) Inhibidores de la actividad de la akt.
ATE456565T1 (de) Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren
CO6321225A2 (es) Particulas portadoras sólidas para mejorar la procesabilidad de un agente farmacéutico
EA200970486A1 (ru) Соединения для ингибирования митоза
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
CO6251364A2 (es) Derivados de morfolino pirimidina utilazdos en enfermedades relacionados con mtor quinasa y/o p13k
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
ATE497961T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
CL2008003798A1 (es) Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
EA201290267A1 (ru) Производные диоксабицикло[3.2.1]октан-2,3,4-триола
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
CL2011002925A1 (es) Compuestos derivados de isoquinolin-1(2h)-ona, inhibidores selectivos de la actividad de poli (adp-ribosa) polimerasa parp-1; proceso para prepararlos; composicion farmaceutica; y su uso para tratar una enfermedad mediada por la proteina parp-1.
EA201100391A1 (ru) Соединения, ингибирующие активность семикарбазид-чувствительной аминооксидазы